Kalbe switches focus to biosimilars from generics as Indonesia launches new regs
HONG KONG – Biosimilars are in the spotlight in Indonesia after the government introduced new regulations and one of the largest pharmaceutical companies in Southeast Asia based there said it would consider making this category of drugs its focus going forward.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST